We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -4.17% | 1.15 | 1.10 | 1.20 | 1.20 | 1.15 | 1.20 | 216,341 | 08:44:37 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.29 | 1.56M |
From Apr 2019 to Apr 2024
TIDMPYC
RNS Number : 8746B
Physiomics PLC
12 October 2015
Physiomics plc
("Physiomics" or "the Company")
4th Large Pharma Customer for Virtual Tumour
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a new Virtual Tumour deal with a new pharmaceutical company, the 4(th) large pharma customer for this service.
The project will be performed on a fee-for-service basis.
Dr Mark Chadwick, CEO of Physiomics, commented:
"It is very pleasing that we have further extended the number of large pharmas starting to use Virtual Tumour. We look forward to adding more such customers as the benefits of our model are more widely understood."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million(1) .
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell(R) technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRUGGGUUUPAGQB
(END) Dow Jones Newswires
October 12, 2015 02:00 ET (06:00 GMT)
1 Year Physiomics Chart |
1 Month Physiomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
